目的:探讨纳美芬治疗早产儿原发性呼吸暂停的效果。方法:将98例原发性呼吸暂停早产儿随机分成A组(36例)、B组(32例)和C组(30例),3组早产儿分别给予纳美芬、纳洛酮和氨茶碱治疗,连用3～5天,用药48 h后评价疗效。观察用药48 h内不良反应,用药前及用药1周时查头颅B超了解颅内出血情况。结果:A组显效率及总有效率分别为83.3%和91.7%,均高于B组和C组(P<0.05)。A组和B组高血糖、心率增快、烦躁不安、喂养不耐受、颅内出血等不良反应发生率也低于C组(P<0.05)。结论:应用纳美芬治疗早产儿原发性呼吸暂停有效、合理,不良反应少,值得临床推广使用。 Objective: To investigate the effect of nalmefene in the treatment of premature infants with primary apnea. Methods: A total of 98 premature infants with primary apnea were randomly divided into group A (n = 36), group B (n = 32) and group C (n = 30). Preterm infants were given nalmefene, naloxone and ammonia Theophylline treatment, once every 3 to 5 days, 48 ​​h after treatment evaluation of efficacy. Observation of adverse reactions within 48 h medication, medication and medication 1 week check the head B ultrasound to understand the situation of intracranial hemorrhage. Results: The markedly effective rate and total effective rate in group A were 83.3% and 91.7%, respectively, which were higher than those in group B and C (P <0.05). The incidences of hyperglycemia, fasting heartbeat, irritability, feeding intolerance and intracranial hemorrhage in group A and group B were also lower than those in group C (P <0.05). Conclusion: Nalmefene is effective and reasonable in treating premature infants with primary apnea and is worthy of clinical promotion.